The ability of SD IIV to protect against seasonal influenza virus infection in the elderly is less than vaccine efficacy observed in healthy young adults. The proposed MAS-1-adjuvanted influenza virus vaccine offers the potential for higher seroconversion and seroprotection rates, higher antibody levels, prolonged duration of protective antibodies, HA antigen dose-sparing and cross-protection against antigenically divergent viral strains. This study will determine if the adjuvanted vaccine formulated with one or more of the reduced HA antigen doses is safe. The study will also determine if it is likely to induce an improved HA antibody response (HAI) when compared to SD IIV in healthy adults and HD IIV in elderly subjects. This trial will inform future clinical trials in at-risk populations of older patients.